Biomoda raises $2M for lung cancer diagnostic test

05/10/2010 | American City Business Journals

Biomoda has secured $2 million in funding from three hedge funds to conduct further clinical trials of a diagnostic test to detect lung cancer. "Proceeds from the financing will allow us to continue our clinical trials, submit our findings to the FDA for clearance as a Class III medical device and begin commercialization," said John Cousins, Biomoda's president and CEO.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX